Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?

  title={Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?},
  author={Jess F Peterson and Nidhi Aggarwal and Clayton A. Smith and Susanne M. Gollin and Urvashi Surti and Aleksandar Rajkovic and Steven H. Swerdlow and Svetlana A. Yatsenko},
  pages={18845 - 18862}
Purpose To evaluate the clinical utility, diagnostic yield and rationale of integrating microarray analysis in the clinical diagnosis of hematological malignancies in comparison with classical chromosome karyotyping/fluorescence in situ hybridization (FISH). Methods G-banded chromosome analysis, FISH and microarray studies using customized CGH and CGH+SNP designs were performed on 27 samples from patients with hematological malignancies. A comprehensive comparison of the results obtained by… 
Comparison of Diagnostic Yield of a FISH Panel Against Conventional Cytogenetic Studies for Hematological Malignancies: A South Indian Referral Laboratory Analysis Of 201 Cases
FISH was found to be advantageous in only a subset of HMs and cannot completely replace CCS, and utilization of the two modalities in conjunction or independently should depend on the indicated HM for an optimal approach to detecting chromosomal aberrations.
Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL
Evidence is presented that short tandem repeat (STR) profiling of tumor DNA relative to DNA from healthy cells might identify chromosomal aberrations affecting therapy outcome, which could be used as a prognostic factor for poor outcome in B-ALL, but not in T-ALL.
Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay
The experience with CMA on adult ALL patients is reported and chromosomal microarray analysis (CMA) showed a specificity >99% and a sensitivity of 100% in chronic lymphocytic leukemia (CLL) patients.
The Genomic Era of Clinical Oncology: Integrated Genomic Analysis for Precision Cancer Care
It is anticipated that CMA and NGS will soon become the major diagnostic means for cancer genomic analysis to meet the increasing demands of precision cancer care.
Genomic Characterization of a Metastatic Alveolar Rhabdomyosarcoma Case Using FISH Studies and CGH+SNP Microarray Revealing FOXO1-PAX7 Rearrangement with MYCN and MDM2 Amplification and RB1 Region Loss
This work describes a case where traditional cytogenetic and molecular methods yielded inconclusive results in detecting the FOXO1 gene rearrangement, however, microarray analysis identified the essential FoxO1-PAX7 aberration and additional submicroscopic genomic alterations, including amplification of MYCN and MDM2 and deletion of RB1.
Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations
Ten Kasumi cell lines established in Japan, including five that were previously unknown, have been characterized by SNP microarray and targeted sequencing, and SNP genotyping suggested that patients in Japan are genetically diverse.
High-resolution single nucleotide polymorphism arrays identified an atypical microdeletion of the Williams-Beuren syndrome interval in a patient presenting with a different phenotype.
The first case of a patient presenting with Williams‑Beuren syndrome alongside supravalvular aortic stenosis, autism and cleft palate is described, and an atypical deletion at 7q11.23 is identified.
Applications of Microarray-Based Technologies in Identifying Disease-Associated Single Nucleotide Variations
Microarrays are these days being used to their full potential as elucidated by a variety of studies suggesting that the utility of microarrays will continue to grow in the forthcoming years as viable detection and identification methods.


Array comparative genomic hybridization detects chromosomal abnormalities in hematological cancers that are not detected by conventional cytogenetics.
High sensitivity of oligonucleotide aCGH for potential use in diagnosis and follow-up in patients with hematological neoplasms is demonstrated and suggests that a subset of potentially significant genomic alterations is missed by the currently available cytogenetic techniques.
Chromosomal microarray versus karyotyping for prenatal diagnosis.
In the context of prenatal diagnostic testing, chromosomal microarray analysis identified additional, clinically significant cytogenetic information as compared with karyotyping and was equally efficacious in identifying aneuploidies and unbalanced rearrangements but did not identify balanced translocations and triploidy.
American College of Medical Genetics and Genomics technical standards and guidelines: microarray analysis for chromosome abnormalities in neoplastic disorders
Clinical laboratories in validation of the methods, their consistent use, and interpretation and reporting of results from these microarray methodologies, the American College of Medical Genetics and Genomics has developed the following professional standard and guidelines.
Whole-genome single nucleotide polymorphism array analysis is complementary to classical cytogenetic analysis in the evaluation of lymphoid proliferations.
The combination of cytogenetics and SNP analysis results in a higher overall yield in identifying numerical chromosomal abnormalities than either technique alone.
Focal 9p instability in hematologic neoplasias revealed by comparative genomic hybridization and single‐nucleotide polymorphism microarray analyses
The findings suggest that, in ALL leukemogenesis, loss of CDKN2A and other target genes in the instability region is frequently associated with BCR/ABL1 and IKZF1 dysfunction.
The molecular genetic makeup of acute lymphoblastic leukemia.
  • C. Mullighan
  • Biology
    Hematology. American Society of Hematology. Education Program
  • 2012
Challenges for the future are to comprehensively identify and experimentally validate all genetic alterations driving leukemogenesis and treatment failure in childhood and adult ALL and to implement genomic profiling into the clinical setting to guide risk stratification and targeted therapy.
Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies.